Study guide

20.2 Systemic Immunosuppressive & Biologic Therapies

UEMS European Board of Dermatovenereology Diploma Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Eligibility & Examination Regulations

1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition

2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology

2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns

3 Chapter 3: Dermatopathology & Diagnostic Procedures

3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy

4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology

4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance

5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease

5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders

6 Chapter 6: Hair, Nails & Pigmentary Disorders

6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation

7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease

7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses

8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease

8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease

9 Chapter 9: Autoimmune Bullous Diseases

9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis

10 Chapter 10: Eczematous Disorders, Urticaria & Allergology

10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy

11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis

11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses

12 Chapter 12: Paediatric & Genetic Dermatology

12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa

13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections

13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections

14 Chapter 14: Viral & Fungal Cutaneous Infections

14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses

15 Chapter 15: Sexually Transmitted Infections & Genital Infections

15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis

16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine

16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems

17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours

17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases

18 Chapter 18: Melanocytic Naevi & Melanoma

18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma

19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas

19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas

20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing

20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy

21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures

21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy

22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision

22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review

20.2 Systemic Immunosuppressive & Biologic Therapies

Key Takeaways Explain This Topic AI

Methotrexate is administered as a strictly once-weekly regimen (10–25 mg) paired with mandatory folic acid rescue (5 mg administered 24–48 hours post-dose); accidental daily administration causes life-threatening myelosuppression and acute mucosal ulceration treatable immediately with folinic acid (leucovorin).

Pre-treatment screening for azathioprine requires mandatory TPMT and NUDT15 testing; homozygous null deficiency precipitates fatal bone marrow aplasia and represents an absolute contraindication, while co-prescription with allopurinol or febuxostat triggers catastrophic thioguanine toxicity.

The European consensus pre-biologic screening protocol mandates chest radiography and IGRA to rule out latent tuberculosis (requiring chemoprophylaxis at least 4 weeks prior to biologic initiation), viral hepatitis serology (HBsAg, anti-HBc, anti-HBs, anti-HCV), HIV testing, and completion of all non-live/live vaccinations prior to therapy.

Certolizumab pegol is a PEGylated, Fc-free TNF-alpha inhibitor that does not bind the neonatal Fc receptor (FcRn) and undergoes negligible transplacental transfer or breast milk secretion, establishing it as the biologic of choice during pregnancy and lactation.

IL-17 family inhibitors (secukinumab, ixekizumab, bimekizumab) carry class-specific risks of mucocutaneous candidiasis and new-onset or exacerbated inflammatory bowel disease, while oral JAK inhibitors carry European Medicines Agency warnings regarding MACE, VTE, malignancies, and herpes zoster reactivation.

Last updated: September 2026

  • 20.2 Systemic Immunosuppressive & Biologic Therapies
  • Conventional Systemic Immunosuppressants in Dermatovenereology

Conventional disease-modifying antirheumatic drugs (cDMARDs) remain primary systemic options across European healthcare systems due to oral bioavailability, established efficacy, and low acquisition cost.

1. Methotrexate (MTX)

Molecular Mechanism: Methotrexate is a structural analogue of folic acid. While high oncologic doses act via competitive inhibition of dihydrofolate reductase (DHFR) to halt de novo thymidylate and purine synthesis, its low-dose anti-inflammatory actions in dermatology (10–25 mg/week) operate primarily through competitive inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase and thymidylate synthase. AICAR accumulation leads to intracellular accumulation of AMP and extracellular release of adenosine . Extracellular adenosine binds to A2A adenosine receptors on lymphocytes and macrophages, potently suppressing pro-inflammatory cytokine release (TNF-α, IL-12, IFN-γ) and inducing activated T-cell apoptosis.

Dosing Schedule & Critical Warning: MTX is administered strictly ONCE WEEKLY (10 to 25 mg/week), taken orally or via subcutaneous injection. Subcutaneous administration offers higher bioavailability (>90%) with fewer gastrointestinal adverse effects.

Fatal Prescribing Pitfall: Accidental daily administration of MTX is a catastrophic medical emergency causing profound bone marrow aplasia, severe agranulocytic sepsis, and diffuse gastrointestinal/cutaneous necrotizing ulcerations.

Mandatory Folic Acid Supplementation: Folic acid ( 5 mg once or twice weekly , taken 24 to 48 hours after the MTX dose, or 1 mg daily except on the MTX administration day) is mandatory. This protects against mucosal ulceration, nausea, transaminitis, and megaloblastic cytopenias without blunting therapeutic efficacy.

Emergency Rescue with Folinic Acid (Leucovorin): In cases of acute overdose or sudden pancytopenia, calcium folinate (leucovorin) must be administered immediately. Leucovorin bypasses DHFR by directly providing 5-formyl-tetrahydrofolate. Regular folic acid is completely ineffective in acute toxicity because DHFR is competitively blocked.

Pre-Treatment Screening: Complete blood count (CBC) with differential, liver transaminases (ALT, AST, ALP, total bilirubin, albumin), renal function (serum creatinine, eGFR; MTX is 80%–90% eliminated unchanged renally; strictly contraindicated if eGFR <30 mL/min), viral hepatitis serology ( HBsAg, anti-HBc, anti-HBs, anti-HCV ), HIV serology, chest radiography, and pregnancy testing.

Teratogenicity & Contraception: Potent teratogen and abortifacient (causes fetal aminopterin syndrome: cranial dysostosis, facial dysmorphism, cardiac defects). Women of childbearing potential need effective contraception during treatment and for at least 6 months afterwards (EU product information). Advice for men varies between product labels and doses; check the current SmPC.

Monitoring Cumulative Hepatotoxicity: Serial liver biopsies have been largely replaced in European guidelines by non-invasive biomarkers:

Serum Procollagen III N-terminal Peptide (PIIINP): Measured every 3 months. Persistent elevations (>4.2 µg/L in at least 3 samples over a 12-month period) indicate active hepatic fibrogenesis, warranting dosage reduction, hepatology referral, or transient elastography.

Transient Elastography (FibroScan): Measures liver stiffness. Values <7.0 to 7.5 kPa reliably exclude advanced fibrosis; values >7.5 to 9.5 kPa indicate suspected fibrosis requiring specialist evaluation.

Acute Idiosyncratic Hypersensitivity Pneumonitis: Characterized by acute dry cough, dyspnoea, fever, and bilateral interstitial/alveolar infiltrates on imaging. It is non-dose-dependent and requires immediate MTX cessation and high-dose systemic corticosteroid therapy.

2. Ciclosporin A (Cyclosporine)

Molecular Mechanism: A neutral cyclic peptide of 11 amino acids. It binds to the intracellular immunophilin cyclophilin A . The resulting drug-cyclophilin complex binds with high affinity to and inhibits calcineurin , a calcium- and calmodulin-activated protein phosphatase. This blocks the dephosphorylation of NFATc , halting its nuclear translocation and silencing transcription of IL-2 (the primary autocrine growth factor driving T-cell clonal expansion) as well as IL-3, IL-4, TNF-α, and IFN-γ.

Clinical Dosing & Rescue Utility: Dosed at 2.5 to 5.0 mg/kg/day in two divided doses 12 hours apart. Characterized by rapid clinical onset (within 1 to 2 weeks), making it the premier short-term "crisis buster" for acute erythrodermic psoriasis, severe atopic flares, and acute pyoderma gangrenosum.

Duration Threshold: Restricted to short-term therapy ( typically ≤12 to 16 weeks , maximum 1 to 2 years continuous) to avoid irreversible renal structural damage.

Nephrotoxicity & The 25–30% Creatinine Rule: Ciclosporin induces acute dose-dependent vasoconstriction of afferent glomerular arterioles (functional nephrotoxicity). Prolonged use leads to structural nephrotoxicity characterized by striped interstitial fibrosis and tubular atrophy.

Monitoring Rule: Blood pressure and serum creatinine must be checked every 2 weeks for the first 3 months, then monthly. If serum creatinine rises more than 25% above the patient's pre-treatment baseline (the EU product information threshold; some guidelines use 30%) on repeated measurement, the dose must be reduced by 25% to 50% . If creatinine does not return to within that range, ciclosporin must be discontinued .

Hypertension Management: Up to 30%–50% of patients develop arterial hypertension. The first-line antihypertensive agents are dihydropyridine calcium channel blockers (e.g., amlodipine , nifedipine), which counteract afferent arteriolar vasoconstriction.

Pharmacokinetic Trap: Non-dihydropyridine CCBs ( diltiazem, verapamil ) are strictly contraindicated because they potently inhibit CYP3A4 , precipitating massive toxic surges in serum ciclosporin levels.

Electrolytes & Cutaneous Toxicities: Induces hypomagnesaemia (renal magnesium wasting), hyperkalaemia , gingival hyperplasia (accentuated by poor oral hygiene and calcium channel blockers), hypertrichosis , and tremors.

Photocarcinogenesis Interaction: Markedly elevates the risk of non-melanoma skin cancer (cutaneous squamous cell carcinoma) and lymphoma, especially in patients with prior extensive PUVA phototherapy (>200 sessions). Concurrent phototherapy with ciclosporin is strictly contraindicated.

3. Azathioprine (AZA)

Molecular Mechanism: A prodrug that undergoes non-enzymatic cleavage by glutathione to 6-mercaptopurine (6-MP) . 6-MP is subsequently metabolized through three competing enzymatic pathways:

Thiopurine S-methyltransferase (TPMT): Inactivates 6-MP to 6-methylmercaptopurine (6-MMP) (excess 6-MMP drives hepatotoxicity).

Xanthine oxidase (XO): Oxidizes 6-MP to inactive 6-thiouric acid .

Hypoxanthine-guanine phosphoribosyltransferase (HGPRT): Converts 6-MP into 6-thioguanine nucleotides (6-TGN) . Active 6-TGN metabolites incorporate into leukocyte DNA and RNA, inducing chromosome breaks, blocking de novo purine synthesis, inhibiting Rac1, and triggering T-lymphocyte apoptosis.

NUDT15 Gene: Encodes nudix hydrolase 15, which cleanses toxic 6-thio-dGTP. Loss-of-function variants in NUDT15 precipitate severe early myelosuppression and acute alopecia (predominantly in Asian and Hispanic populations).

Mandatory Pharmacogenomic Screening: Testing for TPMT and NUDT15 (genotyping or TPMT red blood cell enzymatic phenotyping) is mandatory before prescribing azathioprine:

Normal / High TPMT Activity: Standard dosing of 2.0 to 2.5 mg/kg/day .

Intermediate TPMT Activity (Heterozygous, ~10% of European population): Reduce starting dose by 50% ( 1.0 to 1.5 mg/kg/day ) with frequent hematological monitoring.

Low or Deficient TPMT Activity (Homozygous Null, ~1 in 300 individuals): ABSOLUTE CONTRAINDICATION! Standard doses cause fatal bone marrow aplasia and profound agranulocytosis.

Lethal Drug Interaction with Xanthine Oxidase Inhibitors: Co-administration of azathioprine with allopurinol or febuxostat completely blocks xanthine oxidase. This shunts the entirety of 6-MP into the HGPRT pathway, driving astronomical levels of cytotoxic 6-TGN and triggering fatal bone marrow suppression. If combination cannot be avoided, the azathioprine dose must be drastically slashed to 25% of standard dose (a 75% reduction) with intense CBC surveillance.

4. Mycophenolate Mofetil (MMF) & Enteric-Coated Mycophenolic Acid (EC-MPS)

Molecular Mechanism: MMF is the 2-morpholinoethyl ester prodrug of mycophenolic acid (MPA) . MPA is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH) , specifically the type II isoform expressed predominantly in activated lymphocytes. IMPDH is the rate-limiting enzyme in the de novo synthesis of guanine nucleotides. While other human cells can salvage purines via the hypoxanthine-guanine phosphoribosyltransferase pathway, T and B lymphocytes lack significant salvage pathways and depend exclusively on de novo synthesis. IMPDH inhibition depletes intracellular dGTP, selectively suppressing lymphocyte proliferation, antibody production, and cell adhesion.

Clinical Indications: Autoimmune bullous diseases (pemphigus vulgaris, bullous pemphigoid), pyoderma gangrenosum, cutaneous lupus erythematosus, and dermatomyositis.

Adverse Effects: Dose-limiting gastrointestinal distress (nausea, diarrhea, abdominal cramps; enteric-coated EC-MPS improves upper GI tolerability), myelosuppression (neutropenia), and opportunistic viral infections (HSV, VZV, CMV).

Severe Teratogenicity (Mycophenolate Embryopathy): Causes spontaneous first-trimester pregnancy loss (>40%) and severe structural malformations: microtia/anotia with external auditory canal atresia, cleft lip and palate , micrognathia, ocular coloboma, and congenital heart defects. Strict dual contraception is required 1 month before, during, and for at least 6 weeks post-discontinuation in women (and 90 days in men).

Standardized European Pre-Biologic Screening Protocol

Prior to the initiation of any biologic or targeted synthetic DMARD in dermatovenereology, European consensus guidelines mandate a structured baseline screening protocol to mitigate infection, malignancy, and organ toxicity.

Pre-Biologic Screening Checklist Table

Screening Domain Mandatory Diagnostic Modality Clinical Diagnostic Threshold & Actionable Management Protocol

Latent Tuberculosis (TB) Posterior-anterior Chest X-ray AND ; Interferon-Gamma Release Assay (IGRA: QuantiFERON-TB Gold or T-SPOT.TB) - Active TB: Treat with standard 4-drug therapy; biologic contraindicated until cleared.; - Latent TB (Positive IGRA with normal CXR and no active symptoms): Chemoprophylaxis with Isoniazid for 9 months (or Rifampicin + Isoniazid for 3 months ).; - Mandatory 4-Week Rule: Biologic therapy CANNOT be initiated until at least 4 full weeks of anti-TB chemoprophylaxis have been completed.

Hepatitis B Virus (HBV) Complete Serological Panel:; - HBsAg ; - anti-HBc (total IgG/IgM) ; - anti-HBs - HBsAg Positive: Chronic/active hepatitis B; mandatory hepatology referral and prophylactic antiviral therapy (entecavir or tenofovir) prior to biologic.; - anti-HBc Positive / HBsAg Negative: Resolved/occult HBV; test HBV DNA . If negative, monitor HBV DNA every 2–3 months or initiate preemptive antiviral therapy if using B-cell depleting or potent anti-TNF agents.; - Isolated anti-HBs Positive (>10 IU/L): Immune post-vaccination; safe to proceed.

Hepatitis C Virus (HCV) anti-HCV antibody If positive, quantify HCV RNA . If RNA positive, refer for direct-acting antiviral (DAA) therapy prior to or concurrently with biologic therapy.

Human Immunodeficiency Virus HIV-1/2 antibodies and p24 antigen Controlled HIV (undetectable viral load, stable CD4+ count under antiretroviral therapy) is not an absolute contraindication for IL-23/IL-17 biologics, but mandates infectious disease co-management.

Malignancy Screening Detailed oncologic history and age-appropriate cancer screening (cervical smear, mammography, colonoscopy) Thorough full-body skin examination (TBSE) to rule out undiagnosed melanoma or cutaneous squamous cell carcinoma. Malignancy within the past 5 years (other than treated non-melanoma skin cancer) is a relative contraindication to biologics, especially anti-TNF, and needs a specialist oncology decision.

Infectious Foci Clinical examination, urinalysis, dental check Rule out chronic active infections, infected leg ulcers, or occult dental abscesses before first dose.

Congestive Heart Failure Cardiovascular clinical evaluation (NYHA Functional Class) TNF-alpha inhibitors are ABSOLUTELY CONTRAINDICATED in NYHA Class III and IV heart failure (increased mortality and disease worsening).

Demyelinating Disease Personal or first-degree family history of demyelinating conditions TNF-alpha inhibitors are ABSOLUTELY CONTRAINDICATED in patients with multiple sclerosis, optic neuritis, or transverse myelitis.

Vaccination Status Review vaccination records (Pneumococcal, Influenza, COVID-19, Recombinant Zoster) Update all indicated non-live vaccines. LIVE ATTENUATED VACCINES (e.g., Yellow fever, MMR, Varicella, Oral typhoid, BCG) are ABSOLUTELY CONTRAINDICATED during biologic therapy and must be given at least 4 weeks prior to biologic initiation.

Targeted Biologic Therapies: Molecular Classes & Landmark Pearls

Biologics have revolutionized the management of moderate-to-severe plaque psoriasis and atopic dermatitis by selectively interrupting pathogenic cytokine cascades.

Comparative Biologic Mechanism & Clinical Profile Table

Biologic Class & Generic Name Molecular Target & Structure Primary Dermatologic Indications Key Landmark Efficacy (PASI 90 / EASI 75) Class-Specific Safety Signals & Regulatory Warnings

TNF-α Inhibitors: ; - Adalimumab; - Infliximab; - Etanercept; - Certolizumab pegol Soluble and transmembrane TNF-α; (Certolizumab pegol is an Fc-free PEGylated Fab' fragment) Plaque psoriasis, Psoriatic arthritis, Hidradenitis suppurativa PASI 90: roughly 20%–55% at Week 16 (etanercept lowest; adalimumab/infliximab highest) Latent TB reactivation, demyelinating disease (MS), worsening NYHA III/IV heart failure, drug-induced lupus, paradoxical psoriasis. Certolizumab pegol is safe in pregnancy and lactation!

IL-12/23 Inhibitor: ; - Ustekinumab p40 subunit shared by IL-12 and IL-23 (fully human IgG1κ mAb) Plaque psoriasis, Psoriatic arthritis PASI 90: ~40% at Week 12 (Weight-tiered: 45 mg ≤100 kg, 90 mg >100 kg) Excellent long-term registry safety track record; very low TB reactivation risk; no association with candidiasis or IBD exacerbation.

Selective IL-23 p19 Inhibitors: ; - Guselkumab; - Risankizumab; - Tildrakizumab Unique p19 subunit of IL-23 (sparing IL-12 and Th1 immunity) Plaque psoriasis, Psoriatic arthritis PASI 90: ~70%–75% at Week 16 for guselkumab and risankizumab (lower for tildrakizumab); durable maintenance (q8w or q12w dosing) Superior efficacy; exceptionally low risk of candidiasis; negligible TB reactivation; safe in patients with concurrent IBD.

IL-17 Family Inhibitors: ; - Secukinumab (IL-17A); - Ixekizumab (IL-17A); - Bimekizumab (IL-17A & IL-17F); - Brodalumab (IL-17RA) IL-17A homodimer, IL-17F homodimer, or IL-17 Receptor A Plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis PASI 90: ~55%–90% at Week 12–16 (secukinumab lower, ixekizumab/brodalumab ~70%, bimekizumab ~85%–90% with ~60% PASI 100) Mucocutaneous candidiasis (oral/genital); new-onset or exacerbated Inflammatory Bowel Disease (Crohn disease) ; Brodalumab carries suicidal ideation regulatory warnings.

IL-4 / IL-13 Inhibitors: ; - Dupilumab (anti-IL-4Rα); - Tralokinumab (anti-IL-13) Shared IL-4Rα subunit (blocking IL-4 and IL-13) or soluble IL-13 cytokine Moderate-to-severe atopic dermatitis, Prurigo nodularis EASI 75 at Week 16: dupilumab ~45%–50% as monotherapy (~65%–70% with topical steroids); tralokinumab lower; rapid pruritus reduction Allergic conjunctivitis / blepharitis (10%–25%); paradoxical head and neck erythema ("dupilumab facial redness"); transient peripheral hypereosinophilia.

Critical Clinical Class Pearls

Certolizumab Pegol in Pregnancy: Consists of a humanized Fab' antigen-binding fragment conjugated to polyethylene glycol (PEG), completely lacking an Fc crystallizable region . Because transplacental transfer during the second and third trimesters relies strictly on active transport via the neonatal Fc receptor (FcRn) , certolizumab pegol does not cross the placenta and does not pass into breast milk in clinically meaningful quantities. It is the biologic of choice for women of childbearing potential, during pregnancy, and throughout lactation .

IL-17 Blockade and Mucocutaneous Candidiasis: IL-17A and IL-17F are essential for mucosal epithelial defence against Candida albicans (inducing antimicrobial peptides, defensins, and neutrophil recruitment). Up to 10%–15% of patients treated with IL-17 inhibitors (especially dual IL-17A/F blockade with bimekizumab) develop mild-to-moderate oral or vulvovaginal candidiasis, easily managed with topical antifungals or oral fluconazole without drug discontinuation.

IL-17 Blockade and Inflammatory Bowel Disease (IBD): IL-17 maintains tight junctions and mucosal integrity in the gut epithelium. Neutralization of IL-17 can trigger new-onset Crohn disease or ulcerative colitis, or provoke catastrophic flares of quiescent IBD. IL-17 inhibitors are contraindicated in patients with active or severe IBD .

Small-Molecule Targeted Synthetic DMARDs (tsDMARDs)

Targeted small molecules provide oral therapeutic alternatives to injectable biologics, acting downstream inside immune cells.

1. Phosphodiesterase-4 (PDE4) Inhibitor: Apremilast

Molecular Mechanism: Oral small molecule that selectively inhibits phosphodiesterase-4 (PDE4) , preventing the degradation of intracellular cyclic adenosine monophosphate (cAMP) . Elevated cAMP levels activate protein kinase A (PKA), which downregulates NF-κB-driven pro-inflammatory cytokines ( TNF-α , IL-23 , IL-17 ) while upregulating the potent anti-inflammatory cytokine IL-10 .

Clinical Indications: Moderate plaque psoriasis, psoriatic arthritis, and oral aphthae of Behçet disease.

The Key Advantage: Requires ZERO mandatory routine laboratory blood monitoring! It does not cause bone marrow suppression, hepatotoxicity, nephrotoxicity, or latent TB reactivation.

Adverse Effects: Nausea and diarrhea occur in up to 15%–20% of patients during the initial 2 to 4 weeks of therapy (mitigated by a 5-day dose-titration pack to 30 mg twice daily). Causes mild weight loss (monitor body weight) and carries a regulatory warning regarding new-onset depression or suicidal ideation .

2. Oral Janus Kinase (JAK) Inhibitors

Agents & Targets: Tofacitinib (JAK1/JAK3), Baricitinib (JAK1/JAK2), Upadacitinib (selective JAK1), and Abrocitinib (selective JAK1).

Mechanism: Reversibly bind to the adenosine triphosphate (ATP)-binding pocket of the JAK catalytic domain, preventing transphosphorylation and recruitment of signal transducers and activators of transcription (STAT) . By interrupting the intracellular JAK-STAT pathway , they block the signaling cascades of multiple key inflammatory cytokines simultaneously (IL-4, IL-13, IL-31 [the principal neuroimmune pruritus cytokine], IL-22, IFN-α, and IFN-γ). In atopic dermatitis, oral JAK1 inhibitors deliver near-instantaneous pruritus relief (often within 24 to 48 hours).

European Medicines Agency (EMA) Class-Wide Safety Warnings: Following the post-marketing ORAL Surveillance study, the EMA Pharmacovigilance Risk Assessment Committee (PRAC) issued strict class-wide safety restrictions for all systemic JAK inhibitors:

Major Adverse Cardiovascular Events (MACE): Elevated incidence of myocardial infarction and ischemic stroke.

Venous Thromboembolism (VTE): Deep vein thrombosis (DVT) and pulmonary embolism (PE).

Malignancies: Non-melanoma skin cancer (NMSC), lymphoma, and lung cancer.

Serious Infections & Herpes Zoster: High rates of varicella-zoster virus reactivation (recombinant zoster vaccination [Shingrix] is strongly recommended prior to therapy).

All-Cause Mortality: Increased in older cohorts.

EMA Prescribing Mandate: In patients aged ≥65 years , patients with history of smoking or current smokers , patients with established cardiovascular disease , or patients with risk factors for malignancy or VTE , JAK inhibitors should be used only if no suitable treatment alternatives are available , and administered at the lowest effective dose.

Required Laboratory Monitoring: CBC (anemia, neutropenia, lymphopenia), fasting lipid profile (dose-dependent increases in total cholesterol, LDL, and HDL at 4–12 weeks), liver enzymes, renal function, and creatine phosphokinase (CPK) .

Loading diagram... European Pre-Biologic Screening and Management Decision Tree